IL13RA1 and primary cutaneous T-cell non-Hodgkin lymphoma: One suggested mechanism for the potential acceleration of CTCL progression by dupilumab involves an increase in the availability of IL-13 for binding at the IL-13 receptor (IL-13R) α2 site due to the indirect blockade of the IL-13Rα1 site by dupilumab [42].